Upregulation of GPR109A in Parkinson's disease.

Upregulation of GPR109A in Parkinson's disease.
复制标题

DOI:
10.1371/journal.pone.0109818
复制
发表时间:
2014
期刊:
影响因子:
3.7
通讯作者:
Morgan J
Morgan J
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Wakade C;Chong R;Bradley E;Thomas B;Morgan J

文献摘要

参考文献

被引文献

相似文献

Anecdotal animal and human studies have implicated the symptomatic and neuroprotective roles of niacin in Parkinson’s disease (PD). Niacin has a high affinity for GPR109A, an anti-inflammatory receptor. Niacin is also thought to be involved in the regulation of circadian rhythm. Here we evaluated the relationships among the receptor, niacin levels and EEG night-sleep in individuals with PD. GPR109A expression (blood and brain), niacin index (NAD-NADP ratio) and cytokine markers (blood) were analyzed. Measures of night-sleep function (EEG) and perceived sleep quality (questionnaire) were assessed. We observed significant up-regulation of GPR109A expression in the blood as well as in the substantia nigra (SN) in the PD group compared to age-matched controls. Confocal microscopy demonstrated co-localization of GPR109A staining with microglia in PD SN. Pro and anti-inflammatory cytokines did not show significant differences between the groups; however IL1-β, IL-4 and IL-7 showed an upward trend in PD. Time to sleep (sleep latency), EEG REM and sleep efficiency were different between PD and age-matched controls. Niacin levels were lower in PD and were associated with increased frequency of experiencing body pain and decreased duration of deep sleep. The findings of associations among the GPR109A receptor, niacin levels and night-sleep function in individuals with PD are novel. Further studies are needed to understand the pathophysiological mechanisms of action of niacin, GPR109A expression and their associations with night-sleep function. It would be also crucial to study GPR109A expression in neurons, astrocytes, and microglia in PD. A clinical trial to determine the symptomatic and/or neuroprotective effect of niacin supplementation is warranted.
DOI: 10.1007/s11883-013-0325-9
发表时间: 2013-05
影响因子: 5.8
作者:
Chai, Joshua T.;Digby, Janet E.;Choudhury, Robin P.
通讯作者: Choudhury, Robin P.
DOI: 10.1042/cs0560089
发表时间: 1979-01-01
期刊: CLINICAL SCIENCE AND MOLECULAR MEDICINE
影响因子: --
作者:
BENDER, DA;EARL, CJ;LEES, AJ
通讯作者: LEES, AJ
DOI: 10.1016/j.atherosclerosis.2008.04.044
发表时间: 2009-01-01
期刊: ATHEROSCLEROSIS
影响因子: 5.3
作者:
Ganji, Shobha H.;Qin, Shucun;Kashyap, Moti L.
通讯作者: Kashyap, Moti L.
DOI: 10.1016/j.cell.2013.05.027
发表时间: 2013-06-20
期刊: Cell
影响因子: 64.5
作者:
Chang HC;Guarente L
通讯作者: Guarente L
DOI: 10.1212/wnl.0b013e3181d5a4a3
发表时间: 2010-03-23
期刊: NEUROLOGY
影响因子: 9.9
作者:
Gagne, Joshua J.;Power, Melinda C.
通讯作者: Power, Melinda C.